Side-by-side · Research reference

5-Amino-1MQvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 3Reviewed8/39 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

5-Amino-1MQ

Thymosin α-1

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

—

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

5-Amino-1MQ

Thymosin α-1

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

—

Frequency

Once daily, fasted

2× weekly (Mon/Thu typical)

Lower / starter dose

50 mg / day

0.8 mg per injection

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Duration

8–12 weeks per cycle

6–12 months for chronic indications

Form

Oral capsule

—

Timing

Morning fasted preferred

No specific time

Half-life

Hours (estimated; no human PK published)

~2 hours plasma; tissue effect days

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Reconstitution

—

Sterile water for injection per vial label

04Side Effects & Safety

Parameter

5-Amino-1MQ

Thymosin α-1

GI symptoms

Mild nausea (anecdotal)

Rare nausea

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

No signal — used as adjuvant in oncology

Pregnancy / OB

Avoid

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Injection site reaction

—

Erythema, mild discomfort

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

5-Amino-1MQ

Thymosin α-1

1. Form

Oral capsule. No injection.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Administration

Take with water, fasted preferred.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Timing

Morning fasted.

2× weekly, e.g. Monday + Thursday.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Caveat

Monitor B-vitamin status with chronic use.

27–31G, 4–8 mm insulin syringe.